RECRUITING

Counseling for Harm Reduction and Retention in Medication-assisted Treatment - Cherokee Nation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this randomized clinical trial is to test the efficacy of a program meant to enhance Counseling for Harm Reduction and Retention in MAT in Cherokee Nation (CHaRRM-CN). The main questions it aims to answer are whether CHaRRM-CN: improves retention of patients in MAT, decreases substance-related harm and illicit opioid use, and increases cultural connectedness. After providing written, informed consent, participants will attend a baseline assessement and will then be randomized to either the CHaRRM-CN or treatment as usual group. For 6 months after randomization, participants will be exposed to CHaRRM-CN or treatment as usual. During that time, participants will also attend the 1-month, 3-month and 6-month follow-ups to track their progress through the programs. After the 6 months of either treatment condition, investigators will compare the groups to see if they differ on retention, substance-use outcomes and Native enculturation.

Official Title

Counseling for Harm Reduction and Retention in Medication-assisted Treatment - Cherokee Nation

Quick Facts

Study Start:2023-01-17
Study Completion:2025-07-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05733442

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. At least 18 years of age
  2. 2. Must be newly registered (within 4 weeks) in the CNHS MAT Program. (Prior patients can participate as long as their most recent treatment course was at least 6 months prior).
  3. 3. Must be willing to provide written informed consent to enroll in this study
  1. 1. Refusal or inability to consent to participation in research. (The latter is assessed using the UCSD Brief Assessment of Capacity to Consent.)
  2. 2. Refusal or inability to consent and constituting a risk to the safety and security of other patients or staff

Contacts and Locations

Study Contact

Susan E Collins, PhD
CONTACT
2068327885
collinss@uw.edu
Lonnie A Nelson, PhD
CONTACT
5734240888
lonnie.nelson@wsu.edu

Principal Investigator

Lonnie A Nelson, PhD
PRINCIPAL_INVESTIGATOR
Washington State University
Susan E Collins, PhD
PRINCIPAL_INVESTIGATOR
University of Washington
Ashley Lincoln, MSW
PRINCIPAL_INVESTIGATOR
Cherokee Nation Health Services

Study Locations (Sites)

Cherokee Nation Health Services
Tahlequah, Oklahoma, 74464
United States
University of Washington School of Medicine
Seattle, Washington, 98195
United States

Collaborators and Investigators

Sponsor: Washington State University

  • Lonnie A Nelson, PhD, PRINCIPAL_INVESTIGATOR, Washington State University
  • Susan E Collins, PhD, PRINCIPAL_INVESTIGATOR, University of Washington
  • Ashley Lincoln, MSW, PRINCIPAL_INVESTIGATOR, Cherokee Nation Health Services

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-01-17
Study Completion Date2025-07-31

Study Record Updates

Study Start Date2023-01-17
Study Completion Date2025-07-31

Terms related to this study

Keywords Provided by Researchers

  • opioid use disorder
  • harm reduction
  • medication assisted treatment
  • American Indian

Additional Relevant MeSH Terms

  • Opioid Use Disorder